Offering clinical whole-genome sequencing (WGS) to every child with suspected cancer changes the treatment plan in around one in 14 patients, suggests an analysis of data from two English hospitals where the test is routinely offered. Senior author, professor Sam Behjati, from the Wellcome Sanger Institute, Cambridge University Hospitals, and…

A team of scientists led by deCODE genetics, now part of Amgen, report the first findings from a project to collect whole genome sequence (WGS) from more than 150,000 individuals in the UK Biobank. The UK Biobank is a much-used resource in human genetics research. Set up in 2006, it…

Nebula Genomics, a personal genomics company whose co-founders include George Church, PhD, has launched a platform enabling users to have their whole genome sequenced in return for sharing access to their genomic data. Users seeking immediate sequencing of their personal genome can buy the service starting at $99—a reduction in…

Genomic health intelligence company Human Longevity Inc. (HLI) recently announced an agreement with Massachusetts Mutual Life Insurance (MassMutual) to offer at a reduced price HLIQ Whole Genome, HLI’s whole genome sequencing product to eligible MassMutual customers, employees, and financial partners. “MassMutual has long believed that both financial and physical health are…

Researchers at The University of Texas Health Science Center at Houston (UTHealth) have just developed a framework to understand how whole genome sequence (WGS) data can be analyzed to identify genetic variations that raise or lower risk of disease. The findings from this new study were published recently in the American…

Researchers from The University of Texas at San Antonio (UTSA) have harnessed the power of next-generation sequencing to develop innovative strategies for tracking disease-causing pathogens like E. coli. The investigators hope their new study—“Whole Genome Sequencing for Genomics-Guided Investigations of Escherichia coli O157: H7 Outbreaks”—published recently in Frontiers in Microbiology,…

Whole genome sequencing (WGS) is well on its way to transforming medicine. However, there are a few bumps on the road that WGS needs to overcome before it can become a broadly used and increasingly effective tool for the clinic. Current limitations include the need for WGS tests to be…

Sponsor: This webinar focuses on scientific, clinical, and patient-oriented strategies to help WGS’s high clinical expectations.

A potential landmark genetic association study for the neurodegenerative disorder Parkinson’s has uncovered a new risk variant. The team, which included scientists from the University Medical Center Utrecht, Indiana University School of Medicine, and UMass Chan Medical School, combined whole genome and exome sequencing data from 2184 familial Parkinson’s disease…

Sponsored content brought to you by In 2003, when the Human Genome Project produced sequences of about 90% of the genome, scientists and clinicians wondered when this technology would change healthcare. Meeting that goal depended on technology that could sequence a person’s genome quickly, accurately, and affordably. Through a collection…

VIEW NOW Broadcast Date: October 8, 2020Time: 9:00 am PT, 12:00 pm ET, 18:00 CET In 2010, a team of geneticists and bioinformaticians at Medical College Wisconsin embarked on an ambitious clinical genome sequencing project to end the diagnostic odyssey of a young boy, Nicholas Volker. That project, led by…

Blue Shield of California announced Monday that it will cover the cost of the rapid and ultra-rapid whole-genome sequencing developed by Rady Children’s Institute for Genomic Medicine (RCIGM) to help diagnose critically ill children in intensive care with unexplained medical conditions. The coverage decision from the private payer comes as…

The human genome project cost $3 billion and attracted high expectations about the impact its completion would have on human health both in treating disease and revolutionizing drug development. The greater affordability of and advances in sequencing technology made since the project was completed in 2003 (see “Human Genome at…

PerkinElmer said it will provide support services to the Whole Genome Sequencing (WGS) Diagnostic Program of In-Depth Genomics (IDG) through a collaboration designed to bring genetic diagnosis to neurology patients across a range of conditions that include rare and orphan disorders. Through the collaboration—whose value was not disclosed—PerkinElmer Genetics, the…

The diagnostic work up of most malignant tumors is not complete unless the work up includes genomic characterization. At the time of diagnosis this may consist of a panel of prognostic and/or predictive analyses performed using cytogenetics, fluorescence in situ hybridization, standard molecular technologies, and next-generation sequencing (NGS). Whereas genomic…